Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
Avapro
Generic name / active ingredient
irbesartan
Dosage-form class
Dosage form and presentation as documented in the linked primary label
Route
Oral
Record reviewed
2026-08-30

Copy from the pack in hand

Source-linked reading points

  • 150 mg and 300 mg are labelled strengths per tablet in the U.S. label, not a web answer to how many tablets anyone should take today. Check AVAPRO, irbesartan, strength per tablet, film-coated tablet, actual pack and target market together.
  • The label describes 150 mg and 300 mg as distinct tablets. Package numbers, tablet appearance or a shared ‘blood-pressure medicine’ description do not authorise self-adjusting, splitting, alternating, catch-up use or replacing with another product. Such questions must return to the current label, prescription and pharmacist/clinician review for the exact product.
  • The label contains checks involving other blood-pressure medicines, diuretics, potassium supplements or salt substitutes, NSAIDs and lithium. With cardiovascular, kidney, pain, cold or supplement products, have a professional review the actual packs and complete medicine list together; different names do not establish that co-use is safe.
  • The label includes pregnancy, low-blood-pressure and kidney-function warnings. With fainting, marked weakness, a serious concern, or pregnancy/planning pregnancy, dehydration or kidney concerns, use local medical and prescribing-team pathways promptly; this page does not decide whether to self-continue, stop or switch.

Reviewed presentation examples — compare every field

  • 150 mg per tablet; 30-tablet bottleNDC 0024-5851-30
  • 300 mg per tablet; 30-tablet bottleNDC 0024-5852-30

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-30
Source record
2 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image